BiotechTube
Proxima

Proxima

Cambridge, United States· Est.
proximabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $80M

Overview

Proxima is a private, pre-clinical-stage biotech founded in 2018, focused on pioneering the proximity modulator drug modality through an AI-driven platform. The company has secured significant funding, including an $80 million seed round, and has established a high-value strategic collaboration with Halda Therapeutics. With a newly strengthened Scientific Advisory Board, Proxima is positioning itself at the intersection of generative AI and next-generation drug discovery to target previously undruggable protein interfaces.

AI / Machine Learning

Technology Platform

Integrated AI-driven platform combining a structural proteomics data generation engine with generative AI models to decode protein interfaces and design proximity-based therapeutics (inducers, modulators, blockers).

Funding History

1
Total raised:$80M
PIPE$80M

Opportunities

The company is positioned to tap into the vast, underexplored target space of protein-protein interactions through proximity modulation, a next-generation therapeutic modality.
Its integrated AI and data platform also creates opportunities for multiple high-value partnerships with pharmaceutical companies seeking to accelerate their drug discovery efforts in this area.

Risk Factors

Key risks include the high technical complexity and unproven nature of reliably designing effective proximity modulators via AI, as well as intense competition from both established biotechs and other well-funded AI-drug discovery companies.
Execution risk in delivering on its major partnership is also significant.

Competitive Landscape

Proxima operates in the competitive intersection of AI-driven drug discovery and proximity-based therapeutics, facing rivals like Arvinas and Kymera in the protein degradation space, and AI-native firms such as Recursion, Exscientia, and Isomorphic Labs. Its differentiation lies in the specific integration of structural proteomics data with generative AI focused on protein interfaces.

More companies in Small Molecule Drugs →More companies in United States →